Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(→‎Stage 1: Public Comment Profiles: MSK moved to Consensus)
 
(346 intermediate revisions by 6 users not shown)
Line 1: Line 1:
 
__NOTOC__
 
__NOTOC__
Profiles published here have completed one of the [[QIBA Profile Stages]] of development and been approved by their [[Committees|Biomarker Committee]].
+
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]].
  
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
+
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Consensus Profiles===
+
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
+
 
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 +
 
 +
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists
 +
 
 +
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]
 +
 
 +
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]
 +
 
 +
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
 +
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 +
 
 +
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 +
 
 +
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 +
::*[[Media:QIBA CTA Field Test Checklist.xlsx| Checklists - CTA Atherosclerosis 2020-05-28]]
 +
 
 +
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23
 +
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]
 +
 
 +
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]]
 +
 
 +
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging 2019-12-20]]
 +
 
 +
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]
 +
 
 +
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]
 +
 
 +
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]
 +
 
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]
 +
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]
 +
 
 +
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 +
 
 +
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]]
 +
::*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Checklists - US SWS Appendix E 2022-04-25]]
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
* [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'')
 
  
 +
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
 +
 +
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE Quantification 2020-10-12]] (comments '''closed''' on March 10, 2021)
 +
 +
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)
 +
 +
 +
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
 +
 +
 +
====Format for Citing Profiles====
 +
Cite QIBA Profile documents as:
 +
 +
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''
 +
 +
Example:
 +
 +
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
  
  
==Statements of Endorsement==
+
====Statements of Endorsement====
 
*[[Industry]]
 
*[[Industry]]
 
*[[Clinical Sites]]
 
*[[Clinical Sites]]
Line 20: Line 71:
  
  
==See Also==
+
====See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
*[[Committees|Biomarker Committees]] may link to DRAFT Profile documents for the next Stage.
+
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.
 
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.
 
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')
 
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')
  
 
*[[Work Product for Review]]
 
*[[Work Product for Review]]

Latest revision as of 03:32, 16 November 2022

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also